The effect on COPD susceptibility of up to 95 out of the 97 lung function-associated signals was tested in the COPD study at deCODE Genetics (deCODE COPD study) (1,964 COPD cases and 142,262 controls for single-variant analyses and 1,248 COPD cases and 74,700 controls for risk score analyses), in three lung resection studies: Groningen, Laval and UBC (310 COPD cases and 332 controls), in the following COPD case-control studies: COPDGene Study (2,812 COPD cases and 2,534 controls), Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE) (1,736 COPD cases and 176 controls), National Emphysema Treatment Trial (NETT) and Normative Aging Study (NAS) (NETT/NAS, 376 COPD cases and 435 controls) and the Norway GenKOLS study (Genetics of Chronic Obstructive Lung Disease) (854 cases and 805 controls), in the following eMR studies: Mount Sinai BioMe Biobank (BioMe, 207 COPD cases and 1,817 controls) and Geisinger-Regeneron DiscovEHR Study (DiscovEHR, 1,280 COPD cases and 13,321 controls for single-variant analyses and 1,264 COPD cases and 13,032 controls for risk score analyses), and in UK Biobank (not including UK BiLEVE samples, 984 cases and 26,561
